Business
Zelluna Reaches Major Milestone and Submits Clinical Trial Application in the UK for First-in-Human Study of ZI-MA4-1 (ZIMA-101), the World’s First MAGE-A4-Targeting TCR-NK Cell Therapy for Solid Tumours
On track for initial clinical data in mid-2026Marks a pivotal step toward scalable, accessible, off-the-shelf cell therapies for solid tumours Oslo, Norway, 17 December 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic off-the-shelf cell therapies for cancer, today announced the submission of its Clinical Trial Application (CTA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for ZI-MA4-1, the Company’s lead candidate. The CTA submission marks Zelluna’s transition
About this update from Zelluna Asa
[{"type":"image","alt":"Zelluna ASA","displaySize":"","headline":null,"caption":"Zelluna ASA","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":106,"url":"https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/C3Qdgv86SfCXtr_6x5fSRg--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0ODtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/a3f855525ffb13acd9e8579786771e69","width":300,"height":106}},"lazy":false},{"type":"list","items":[{"val":[{"type":"text","content":"On track for initial clinical data in mid-2026","length":46,"tagName":"p"}]},{"val":[{"type":"text","content":"Marks a pivotal step toward scalable, accessible, off-the-shelf cell therapies for solid tumours","length":96,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":142,"olType":false},{"type":"text","content":"Oslo, Norway, 17 December 2025 – Zelluna (OSE: ZLNA), a company pioneering allogeneic off-the-shelf cell therapies for cancer, today announced the submission of its Clinical Trial Application (CTA) to the UK Medicines and Healthcare products Regulatory Agency (MHRA) for ZI-MA4-1, the Company’s lead candidate.","length":310,"tagName":"p"},{"type":"text","content":"The CTA submission marks Zelluna’s transition from preclinical to clinical development and represents the successful delivery of all key milestones communicated for 2025:","length":170,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Manufacturing process locked (April 2025)","length":41,"tagName":"p"}]},{"val":[{"type":"text","content":"Preclinical data package completed and key data published (December 2025)","length":73,"tagName":"p"}]},{"val":[{"type":"text","content":"GMP clinical batch produced and quality-tested (December 2025)","length":62,"tagName":"p"}]},{"val":[{"type":"text","content":"Clinical Trial Application submitted to the UK MHRA (December 2025)","length":67,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":243,"olType":false},{"type":"text","content":"ZI-MA4-1 is a novel cell therapy that combines two powerful cancer fighting mechanisms: precise solid tumour targeting of T cell receptors (TCRs) with the potent and broad cancer killing ability of Natural Killer (NK) cells. ZI-MA4-1 targets MAGE-A4, a protein found in many solid cancers including lung, ovaria...